AngioDynamics, Inc. (ANGO) Earnings Call Transcripts
AngioDynamics, Inc.'s Latest Earnings Call - June 10, 2026
In the earnings call for Q4 FY2026, AngioDynamics, Inc. highlighted its strategic transformation and strong growth trajectory. The company reported nearly 20% growth in its MedTech segment and an overall company growth of approximately 9%. Management emphasized the success of its Arion and NanoKnife products, contributing to market share gains and high double-digit growth. The company maintains a strong balance sheet with zero debt and ample cash reserves. Forward guidance suggests continued above-market growth rates, with full-year results expected to be in line with Q3's strong performance.
Reported metrics
| Metric | Value |
|---|---|
| MedTech Segment Growth | 20% (beat) |
| Overall Company Growth | 9% (inline) |
| Debt | $0 (positive) |
| Cash Reserves | Plenty of cash (positive) |
Guidance from management
Management expects continued above-market growth rates, with full-year results to align with the strong performance seen in Q3. Guidance remains positive, indicating sustained momentum in key segments.
What analysts pressed on
Analysts may question the sustainability of high growth rates and the competitive landscape, particularly in the cardiovascular and oncology markets. Concerns could also arise regarding the execution of the product pipeline and maintaining market share against larger competitors.
Main topics on the call
- MedTech Segment Growth — The MedTech segment reported nearly 20% growth, driven by products like Arion and NanoKnife. Management stated, 'We're growing our med tech business, nearly 20%.'
- Product Success - Arion — The Arion product for peripheral arterial disease has achieved high double-digit growth and captured significant market share. Management noted, 'We're growing or on in high double digits, just under 20% growth.'
- Product Success - NanoKnife — NanoKnife, used for solid tumor cancers, has shown over 20% growth year-over-year, supported by recent FDA approval and CPT 1 code for reimbursement. 'We expect it to grow and continue to grow at very high double digits ...
- Financial Position — AngioDynamics has a strong financial position with zero debt and sufficient cash reserves, enabling continued investment in growth. 'Today, we have 0 debt. We've got plenty of cash.'
Read the full AngioDynamics, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About AngioDynamics, Inc.
AngioDynamics, Inc. (ANGO) is a publicly listed company in the Health Care Equipment and Supplies industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 46 calls on record spanning January 7, 2020 to October 8, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 46 AngioDynamics, Inc. earnings call transcripts on record, spanning January 7, 2020 to October 8, 2026. Based on this history, AngioDynamics, Inc. reports quarterly. The most recent call on file is dated October 8, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- ANGO
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Calls on record
- 46
- First call
- January 7, 2020
- Most recent
- October 8, 2026
- Reporting cadence
- quarterly